Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.53 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.53 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KLK7 | P49862 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25787604 | 1.00 | HTT (0.61) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL9667908 | 1.00 | HTT (0.61) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL10431132 | 0.99 | HTT (0.63) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL15653279 | 0.98 | HTT (0.59) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL16975020 | 0.95 | HTT (0.68) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL23777326 | 0.90 | TPSAB1 (0.56) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL2417332 | 0.90 | TPSAB1 (0.56) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL6049741 | 0.90 | HTT (0.59) | HTTMAPTTGM2TPSAB1TPSD1 | |
| SCHEMBL15679441 | 0.90 | MAPT (0.64) | HTTMAPTTGM2LMNASMN1; SMN2 | |
| SCHEMBL20385193 | 0.90 | MAPT (0.64) | HTTMAPTTGM2LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110914240-B | Norbornenone compounds releasing carbon monoxide | 奥塔哥创新有限公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20220373541-A1 | Tri-functional Crosslinking Reagents | ETH ZURICH (CH) | 2022-11-24 | — | — | US | disclosed |
| US-20220373541-A1 | Tri-functional Crosslinking Reagents | ETH ZURICH (CH) | 2022-11-24 | — | — | US | disclosed |
| US-11385225-B2 | Tri-functional crosslinking reagents | ETH ZURICH (CH) | 2022-07-12 | — | — | US | disclosed |
| US-11385225-B2 | Tri-functional crosslinking reagents | ETH ZURICH (CH) | 2022-07-12 | — | — | US | disclosed |
| EP-3383846-B1 | CARBON MONOXIDE RELEASING NORBORNENONE COMPOUNDS | OTAGO INNOVATION LTD (NZ) | 2022-06-22 | — | — | EP | disclosed |
| EP-3374348-B1 | TRI-FUNCTIONAL CROSSLINKING REAGENTS | ETH ZUERICH (CH) | 2021-11-24 | — | — | EP | disclosed |
| US-20210032286-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20210024574-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2021-01-28 | — | — | US | disclosed |
| WO-2012067670-A1 | IRINOTECAN IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20110165699-A1 | IRINOTECAN IMMUNOASSAY | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2011-07-07 | — | — | US | disclosed |
| WO-2011071672-A1 | IRINOTECAN IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110136253-A1 | Irinotecan Immunoassay | SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. (CN) | 2011-06-09 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| WO-2008155017-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2007-02-08 | — | — | US | disclosed |
| US-5888971-A | ANTICOAGULANT | ORTHO PHARMACEUTICAL CORPORATION, INC. (US) | 1999-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165699-A1 | IRINOTECAN IMMUNOASSAY | SI, TOP2A, TYMP | HTT 3703/4885MAPT 1138/4885TGM2 485/4885 |
| US-11385225-B2 | Tri-functional crosslinking reagents | ADGRF1, FCGR3B, FCGR2A | HTT 2396/4885MAPT 4677/4885TGM2 1162/4885 |
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | HMGCR, PCSK9, FABP3 | HTT 671/4885MAPT 4638/4885TGM2 926/4885 |
| US-20220373541-A1 | Tri-functional Crosslinking Reagents | ADGRF1, SIGLEC7, ADGRE5 | HTT 2294/4885MAPT 4491/4885TGM2 1682/4885 |
| US-20210032286-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | HTT 4490/4885MAPT 1246/4885TGM2 82/4885 |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CPSF6, NFATC1, CPSF1 | HTT 4139/4885MAPT 2761/4885TGM2 3718/4885 |
| US-20070032653-A1 | N-{1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl}-N-cyclohexylamine; agonists or antagonists of somatostatin receptors; acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites, nesidoblastosis, hyperinsulinism, gastrinoma, etc. | GHSR, IGF1R, GIPR | HTT 1033/4885MAPT 4377/4885TGM2 2089/4885 |
| US-20210024574-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | HTT 4490/4885MAPT 1246/4885TGM2 82/4885 |
| US-20110136253-A1 | Irinotecan Immunoassay | SI, TOP2A, TYMP | HTT 3703/4885MAPT 1138/4885TGM2 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.